HYDERABAD: Pharma main Natco Pharma has clocked a multi-fold (547%) development in consolidated internet revenue for the second quarter ended September 30, 2023, at Rs 369 crore as towards practically Rs 57 crore within the corresponding quarter of monetary 12 months 2022-23.
This was on a 134% leap in consolidated complete income of Rs 1,061 crore for Q2FY24 as in comparison with Rs 453 crore in Q2FY23.
The Hyderabad primarily based firm attributed the efficiency in the course of the quarter to development in formulations exports and elevated gross sales within the home agrochemical enterprise.
Whereas revenues from formulations exports surged practically 180% to Rs 792 crore in Q2FY24 from Rs 283 crore in Q2FY23, revenues from home formulations rose practically 10% to round Rs 103 crore in Q2FY24 from about Rs 94 crore in Q2FY23.
However, revenues from API (lively pharmaceutical elements) in the course of the quarter went up 76% to almost Rs 78 crore as in comparison with Rs 44 crore in Q2FY23 and that from crop well being sciences enterprise soared 1760% to almost Rs 56 crore from simply Rs 3 crore in Q2FY23.
The corporate additionally stated its board of administrators have declared a second interim dividend of Rs 1.25 per fairness share of Rs 2 every for FY 2024.
This was on a 134% leap in consolidated complete income of Rs 1,061 crore for Q2FY24 as in comparison with Rs 453 crore in Q2FY23.
The Hyderabad primarily based firm attributed the efficiency in the course of the quarter to development in formulations exports and elevated gross sales within the home agrochemical enterprise.
Whereas revenues from formulations exports surged practically 180% to Rs 792 crore in Q2FY24 from Rs 283 crore in Q2FY23, revenues from home formulations rose practically 10% to round Rs 103 crore in Q2FY24 from about Rs 94 crore in Q2FY23.
However, revenues from API (lively pharmaceutical elements) in the course of the quarter went up 76% to almost Rs 78 crore as in comparison with Rs 44 crore in Q2FY23 and that from crop well being sciences enterprise soared 1760% to almost Rs 56 crore from simply Rs 3 crore in Q2FY23.
The corporate additionally stated its board of administrators have declared a second interim dividend of Rs 1.25 per fairness share of Rs 2 every for FY 2024.
